ReviewInternational journal of environmental research and public health2021
Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future.
Review in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Balancing Access and Value in Multi-Indication Medicines: Implications of PD-(L)1 Broad Listings in Australia.PharmacoEconomics · 2026Review
- Antipsychotic treatment patterns and cardiometabolic medicine use: current real-world evidence.Epidemiology and psychiatric sciences · 2026Article
- Assessing real-world evidence utilization in oncology health technology assessments: insights from external control-arm studies.Oncology reviews · 2026Article
- Article
- Innovations in pharmacovigilance studies of medicines in older people.British journal of clinical pharmacology · 2025Review
- Enriching Data Science and Health Care Education: Application and Impact of Synthetic Data Sets Through the Health Gym Project.JMIR medical education · 2024Article
- Does Legislation Impede Data Sharing in Australia Across Institutions and Jurisdictions? A Scoping Review.Journal of medical systems · 2023Article
- Integrated Management Systems (IMS) to Support and Sustain Quality One Health Services: International Lessons from the COVID-19 Pandemic by the IMIA Primary Care Working Group.Yearbook of medical informatics · 2023Article
- Investigating the impact of a national educational program on patient adherence to osteoporosis medications.Archives of osteoporosis · 2023Observational
- Health Statistics in Australia: What We Know and Do Not Know.International journal of environmental research and public health · 2022Review
- General Practice Statistics in Australia: Pushing a Round Peg into a Square Hole.International journal of environmental research and public health · 2022Article
- Using electronic admission data to monitor temporal trends in local medication use: Experience from an Australian tertiary teaching hospital.Frontiers in pharmacology · 2022Article
- Patient Selection for Spinal Cord Stimulation in Treatment of Pain: Sequential Decision-Making Model - A Narrative Review.Journal of pain research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Australia spends more than $20 billion annually on medicines, delivering significant health benefits for the population. However, inappropriate prescribing and medicine use also result in harm to individuals and populations, and waste of precious health resources. Medication data linked with other routine collections enable evidence generation in pharmacoepidemiology; the science of quantifying the use, effectiveness and safety of medicines in real-world clinical practice. This review details the history of medicines policy and data access in Australia, the strengths of existing data sources, and the infrastructure and governance enabling and impeding evidence generation in the field. Currently, substantial gaps persist with respect to cohesive, contemporary linked data sources supporting quality use of medicines, effectiveness and safety research; exemplified by Australia's limited capacity to contribute to the global effort in real-world studies of vaccine and disease-modifying treatments for COVID-19. We propose a roadmap to bolster the discipline, and population health more broadly, underpinned by a distinct capability governing and streamlining access to linked data assets for accredited researchers. Robust real-world evidence generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable health care and improve the health and well-being of all Australians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.